What is a stock summary page? Click here for an overview.
Business Description
Eckert & Ziegler SE
ISIN : DE0005659700
Description
Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.88 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | 0.74 | |||||
Interest Coverage | 13.44 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.96 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.5 | |||||
3-Year EBITDA Growth Rate | 11.2 | |||||
3-Year EPS without NRI Growth Rate | 9.3 | |||||
3-Year FCF Growth Rate | -9.1 | |||||
3-Year Book Growth Rate | 14.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 19.59 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.87 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.38 | |||||
9-Day RSI | 41.52 | |||||
14-Day RSI | 45.8 | |||||
3-1 Month Momentum % | 35.82 | |||||
6-1 Month Momentum % | 54.62 | |||||
12-1 Month Momentum % | 68.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.77 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 0.98 | |||||
Days Inventory | 110.94 | |||||
Days Sales Outstanding | 60.43 | |||||
Days Payable | 14.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.09 | |||||
Dividend Payout Ratio | 0.03 | |||||
3-Year Dividend Growth Rate | 5.6 | |||||
Forward Dividend Yield % | 0.09 | |||||
5-Year Yield-on-Cost % | 0.22 | |||||
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 0.12 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.07 | |||||
Operating Margin % | 20.01 | |||||
Net Margin % | 10.58 | |||||
FCF Margin % | 14.82 | |||||
ROE % | 12.49 | |||||
ROA % | 6.41 | |||||
ROIC % | 10.95 | |||||
3-Year ROIIC % | 5.55 | |||||
ROC (Joel Greenblatt) % | 28.29 | |||||
ROCE % | 15.06 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 39.16 | |||||
Forward PE Ratio | 24.15 | |||||
PE Ratio without NRI | 30.64 | |||||
Shiller PE Ratio | 49.27 | |||||
Price-to-Owner-Earnings | 19.46 | |||||
PEG Ratio | 2.43 | |||||
PS Ratio | 4.17 | |||||
PB Ratio | 4.67 | |||||
Price-to-Tangible-Book | 5.91 | |||||
Price-to-Free-Cash-Flow | 28.16 | |||||
Price-to-Operating-Cash-Flow | 18.53 | |||||
EV-to-EBIT | 20 | |||||
EV-to-EBITDA | 15.91 | |||||
EV-to-Revenue | 4.02 | |||||
EV-to-FCF | 27.77 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Projected-FCF | 2.19 | |||||
Price-to-DCF (Earnings Based) | 0.97 | |||||
Price-to-DCF (FCF Based) | 1.51 | |||||
Price-to-Median-PS-Value | 1.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.13 | |||||
Price-to-Graham-Number | 2.84 | |||||
Price-to-Net-Current-Asset-Value | 25.84 | |||||
Earnings Yield (Greenblatt) % | 4.99 | |||||
FCF Yield % | 3.55 | |||||
Forward Rate of Return (Yacktman) % | 11.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Eckert & Ziegler SE Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 277.722 | ||
EPS (TTM) (€) | 1.42 | ||
Beta | 1.44 | ||
3-Year Sharpe Ratio | 0.15 | ||
3-Year Sortino Ratio | 0.25 | ||
Volatility % | 38.73 | ||
14-Day RSI | 45.8 | ||
14-Day ATR (€) | 1.949732 | ||
20-Day SMA (€) | 57.455 | ||
12-1 Month Momentum % | 68.77 | ||
52-Week Range (€) | 29.52739 - 62.05 | ||
Shares Outstanding (Mil) | 20.85 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eckert & Ziegler SE Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eckert & Ziegler SE Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Eckert & Ziegler SE Frequently Asked Questions
What is Eckert & Ziegler SE(XTER:EUZ)'s stock price today?
The current price of XTER:EUZ is €55.55. The 52 week high of XTER:EUZ is €62.05 and 52 week low is €29.53.
When is next earnings date of Eckert & Ziegler SE(XTER:EUZ)?
The next earnings date of Eckert & Ziegler SE(XTER:EUZ) is .
Does Eckert & Ziegler SE(XTER:EUZ) pay dividends? If so, how much?
The Dividend Yield % of Eckert & Ziegler SE(XTER:EUZ) is 0.09% (As of Today), Highest Dividend Payout Ratio of Eckert & Ziegler SE(XTER:EUZ) was 0.44. The lowest was 0.03. And the median was 0.3. The Forward Dividend Yield % of Eckert & Ziegler SE(XTER:EUZ) is 0.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |